Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Neogenomics Inc (NQ: NEO )

15.80 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 24, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Neogenomics Inc

< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
It's time to start the day with a breakdown of the biggest pre-market stock movers worth keeping an eye on for Wednesday! 
Via InvestorPlace
Evaluating NeoGenomics: Insights From 4 Financial Analysts
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
Recap: NeoGenomics Q4 Earnings
Via Benzinga
NeoGenomics Reports Fourth Quarter and Full Year 2023 Results
From NeoGenomics, Inc.
Via Business Wire
NeoGenomics's Earnings Outlook
Via Benzinga
7 Analysts Have This To Say About NeoGenomics
Via Benzinga
What 6 Analyst Ratings Have To Say About NeoGenomics
Via Benzinga
Earnings Scheduled For February 20, 2024
Companies Reporting Before The Bell • Barclays (NYSE:BCS) is likely to report quarterly earnings at $0.36 per share on revenue of $7.38 billion. 
Via Benzinga
NeoGenomics Signs Working with Cancer Pledge in Support of Employees
From NeoGenomics, Inc.
Via Business Wire
Multiple Myeloma Therapeutics Market Expected to Reach $4.26 Billion in 2030
EQNX::TICKER_START (OTCQB:TDSGF),(TSXV:TELO),(NYSE:BMY),(NYSE:TMO),(NASDAQ:NTRA),(NASDAQ:NEO) EQNX::TICKER_END 
Via FinancialNewsMedia
NeoGenomics Reports Third Quarter 2023 Results
Via ACCESSWIRE
Earnings Scheduled For November 6, 2023
Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is expected to report quarterly earnings at $0.16 per share on revenue of $366.82 million. 
Via Benzinga
Multiple Myeloma Therapeutics Market Expected to Reach $4.26 Billion in 2030
From FN Media Group LLC
Via GlobeNewswire
NeoGenomics to Report Fourth Quarter and Full Year 2023 Financial Results on February 20, 2024
From NeoGenomics, Inc.
Via Business Wire
Natera Hits A Nearly Two-Year High After Notching A Win In A Patent Battle
The company must pay $57 million in damages, but that's far less than expected. 
Via Investor's Business Daily
Topics Intellectual Property
Exposures Intellectual Property
Bull of the Day - NeoGenomics
But in late December, shares took a big hit on patent litigation with competitor Natera. Let's review the primary commercial business of NEO and then that will help put the legal news into context. 
Via Talk Markets
Topics Intellectual Property
Exposures Intellectual Property
ROSEN, A LEADING NATIONAL FIRM, Encourages NeoGenomics, Inc. Investors to Inquire About Securities Class Action Investigation – NEO
From The Rosen Law Firm, P.A.
Via Business Wire
NeoGenomics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
From NeoGenomics, Inc.
Via Business Wire
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet
Each week, Benzinga's Stock Whisper Index uses a combination of proprietary data and pattern recognition to showcase five stocks that are just under the surface and warrant attention. 
Via Benzinga
Expedia To Rally Around 10%? Here Are 10 Top Analyst Forecasts For Friday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
Via Benzinga
Why DouYu International Shares Are Trading Higher By 14%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Shares of DouYu International Holdings Limited (NASDAQ: DOYU) rose sharply during Thursday’s session after announcing a share repurchase program. 
Via Benzinga
US Court Prohibits NeoGenomics To Sell Type Of Diagnostic Kits To Detect Smaller Number Of Cancer Cells, Favoring Natera In Lawsuit
Shares of NeoGenomics Inc (NASDAQ: NEO) fell Thursday after the company received a preliminary injunction from a North Carolina district court, which prohibits the company from  
Via Benzinga
Stocks Edge Higher As End Of 2023 Approaches
The SPX is less than 10 points away from record close territory, and with one day left, all three major indexes are heading toward sizable December wins. 
Via Talk Markets
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
NeoGenomics, Energy Fuels And Other Big Stocks Moving Lower On Thursday
U.S. stocks traded higher, with the Dow Jones index gaining around 80 points on Thursday. Shares of NeoGenomics, Inc. (NASDAQ: NEO) shares fell sharply during Thursday’s session after Natera won a... 
Via Benzinga
Topics Intellectual Property Lawsuit Stocks
Exposures Financial Intellectual Property Legal
NeoGenomics to Appeal Ruling
Via ACCESSWIRE
NeoGenomics to Present New Data at San Antonio Breast Cancer Symposium Highlighting Utility of RaDaR for Therapy Response
Via ACCESSWIRE
NeoGenomics to Participate at the Piper Sandler 35th Annual Healthcare Conference
Via ACCESSWIRE
Bull Of The Day: NeoGenomics
NeoGenomics is a small-cap provider of cancer genetics diagnostics. They boast one of the most comprehensive oncology-focused testing menus in the world to help physicians diagnose and treat cancer. 
Via Talk Markets
< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.